Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy

Cancer Treatment Reviews

Volumn 27, Issue 6, 2001, Pages 365-374

  Witkamp, Arjen J ^a   De Bree, Eelco ^a   Van Goethem, R ^a   Zoetmulder, Frans A N ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; MITOMYCIN C; MITOXANTRONE; TAXANE DERIVATIVE; THIOTEPA;

ANAPHYLAXIS; BLOOD TOXICITY; CANCER; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG PENETRATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTHERMIC THERAPY; KIDNEY FAILURE; MINIMAL RESIDUAL DISEASE; NONHUMAN; PERITONEUM METASTASIS; PERITONEUM PSEUDOMYXOMA; PEROPERATIVE CARE; POSTOPERATIVE COMPLICATION; RAT; REVIEW; STOMACH CANCER; SURGICAL TECHNIQUE;

EID: 0035735324     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2001.0232     Document Type: Article

References (71)

1. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin
2. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer
3. High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results
4. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy
5. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
6. Intraperitoneal treatment and dose-intense therapy in ovarian cancer
7. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer
8. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study
9. Peritonectomy procedures
10. Pseudomyxoma peritonei syndrome
11. The treatment of malignancy by hyperthermia
12. Status of clinical hyperthermia
13. Clinical hyperthermia and chemotherapy
14. An update on the anticancer effects of a combination of chemotherapy and hyperthermia
15. Hyperthermic peritoneal perfusion system in canines
16. Clinical delivery system for intraperitoneal hyperthermic chemotherapy
17. Methodologic considerations in treatment using intraperitoneal chemotherapy
18. Management of peritoneal-surface malignancy: The surgeon's role
19. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: Randomised controlled study
20. Hyperthermochemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination
21. Thermic homogeneity and standardization of intraperitoneal chemohyperthermia for peritoneal carcinomatosis
22. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding
23. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin-C
24. Peritoneal expansion by artificially produced ascites during perfusion chemotherapy
25. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration
26. Surgically directed chemotherapy: Heated intraperitoneal lavage with mitomycin C
27. Long term survival of 5 years following initial surgery for gastric cancer and simultaneous disseminated peritoneal metastasis
28. Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion
29. Peritoneal-plasma barrier
30. The minimal importance of hollow viscera to peritoneal transport during peritoneal dialysis in the rat
31. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer
32. Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer
33. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer
34. Hyperthermic intraperitoneal doxorubicin: Pharmacokinetics, metabolism, and tissue distribution in a rat model
35. Study of the pharmakokinetics of mitomycin C in humans during intraperitoneal chemothermia with special mention of the concentration in local tissues
36. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines
37. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma
38. Complications of heated intraperitoneal chemotherapy and strategies for prevention
39. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis
40. Response of peritoneal solid tumors after i.p. chemohyperthermia treatment with cisplatin or carboplatin
41. Penetration of mitomycin C in human bladder
42. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies
43. Extensive surgical cytoreduction and intra-operative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei
44. Peritonectomy and hyperthermic antiblast perfusion in the treatment of peritoneal carcinomatosis
45. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer
46. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy
47. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion
48. Prophylaxix with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer
49. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique
50. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis from colorectal origin
51. Effects of intraperitoneal chemotherapy on anastomotic healing in the rat
52. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomised controlled study
53. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer
54. Intraperitoneal chemohyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis
55. Impact of mitomycin-C kinetics on surgical complications after hyperthermic intraperitoneal chemotherapy (HIPEC)
56. Complications of heated intraperitoneal chemotherapy and strategies for prevention
57. Anaphylaxis from intraperitoneal infusion of cisplatin: A case report
58. Malignant peritoneal mesothelioma treated by continuous hyperthermic peritoneal perfusion chemotherapy
59. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas
60. Extensive cytoreductive surgery combined with intraoperative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: A pilot study
61. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery
62. Prospective randomised trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer
63. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma
64. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases
65. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy
66. Treatment of peritoneal carcinomatosis with intent to cure
67. Peritoneal carcinomatosis treatment with curative intent: The Institut Gustave-Roussy experience
68. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin
69. Hyperthermia in combination with chemotherapy: From laboratory bench to bedside
70. Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis
71. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination